Sort   by:  
 Page size 
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957 | biostudies-literature
UnknownInborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children.
Not available
S-EPMC10451000 | biostudies-literature
UnknownDesign and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Not available
S-EPMC6889917 | biostudies-literature
UnknownFinerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
Not available
S-EPMC9271031 | biostudies-literature
UnknownFinerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Not available
S-EPMC9862372 | biostudies-literature
UnknownDesign and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Not available
S-EPMC6888890 | biostudies-literature
UnknownApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774 | biostudies-literature
UnknownOutcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Not available
S-EPMC10278789 | biostudies-literature
UnknownSARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
Not available
S-EPMC7995808 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604 | biostudies-literature
Sort   by:  
 Page size